{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:18:51Z","timestamp":1792603131561,"version":"4.5.0"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T00:00:00Z","timestamp":1587686400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.jconrel.2020.04.030","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T01:38:01Z","timestamp":1587519481000},"page":"269-281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"special_numbering":"C","title":["Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session"],"prefix":"10.1016","volume":"323","author":[{"given":"Marion M.","family":"Deken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta M.","family":"Kijanka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irati","family":"Beltr\u00e1n Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime D.","family":"Slooter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette S.","family":"de Bruijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"van Diest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.P.","family":"van Bergen en Henegouwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens W.G.M.","family":"Lowik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic J.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander L.","family":"Vahrmeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6011-2122","authenticated-orcid":false,"given":"Sabrina","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jconrel.2020.04.030_bb0005","article-title":"Trastuzumab containing regimens for early breast cancer","author":"Moja","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/annonc\/mdq304","article-title":"Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?","volume":"22","author":"Joerger","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0015","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature01392","article-title":"Structure of the extracellular region of HER2 alone and in complex with the Herceptin fab","volume":"421","author":"Cho","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2020.04.030_bb0020","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0025","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2020.04.030_bb0030","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S1470-2045(14)70320-1","article-title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response","volume":"15","author":"de Azambuja","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0035","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S1470-2045(14)70080-4","article-title":"Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort","volume":"15","author":"Gianni","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0040","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","article-title":"Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831","volume":"32","author":"Perez","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0045","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)61094-6","article-title":"2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial","volume":"382","author":"Goldhirsch","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2020.04.030_bb0050","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","article-title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","volume":"19","author":"Hurvitz","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0055","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","article-title":"Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease","volume":"17","author":"Cobleigh","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0060","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","article-title":"Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer","volume":"20","author":"Vogel","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0065","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","article-title":"Trastuzumab emtansine versus treatment of physician\u2019s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial","volume":"18","author":"Krop","year":"2017","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.jconrel.2020.04.030_bb0070","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0075","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","article-title":"Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer","volume":"28","author":"Blackwell","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0080","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0085","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study","volume":"14","author":"Swain","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9020483","article-title":"Photodynamic therapy in primary breast cancer","volume":"9","author":"Banerjee","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0095","first-page":"9","article-title":"Oncologic photodynamic therapy: basic principles, current clinical status and future directions","author":"van Straten","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2020.04.030_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1039\/b108586g","article-title":"The role of apoptosis in response to photodynamic therapy: what, where, why, and how","volume":"1","author":"Oleinick","year":"2002","journal-title":"Photochem. Photobiol. Sci."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0105","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1021\/cr900300p","article-title":"Imaging and photodynamic therapy: mechanisms, monitoring, and optimization","volume":"110","author":"Celli","year":"2010","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0110","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1038\/nm.2554","article-title":"Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules","volume":"17","author":"Mitsunaga","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0115","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/lsm.20345","article-title":"Targeted photodynamic therapy","volume":"38","author":"Solban","year":"2006","journal-title":"Lasers Surg. Med."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0120","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.nano.2013.12.007","article-title":"Nanobody-photosensitizer conjugates for targeted photodynamic therapy","volume":"10","author":"Heukers","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.04.030_bb0125","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jconrel.2016.03.014","article-title":"EGFR targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer","volume":"229","author":"van Driel","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.04.030_bb0130","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/antib8020026","article-title":"VHH-photosensitizer conjugates for targeted photodynamic therapy of met-overexpressing tumor cells","volume":"8","author":"Heukers","year":"2019","journal-title":"Antibodies"},{"key":"10.1016\/j.jconrel.2020.04.030_bb0135","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1021\/acs.molpharmaceut.9b00360","article-title":"Nanobody-targeted photodynamic therapy selectively kills viral GPCR-expressing glioblastoma cells","volume":"16","author":"De Groof","year":"2019","journal-title":"Mol. Pharm."},{"issue":"5","key":"10.1016\/j.jconrel.2020.04.030_bb0140","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.7150\/thno.37949","article-title":"Acute cellular and vascular responses to photodynamic therapy using EGFR-targeted nanobody-photosensitizer conjugates studied with intravital optical imaging and magnetic resonance imaging","volume":"10","author":"de Bruijn","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2020.04.030_bb0145","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/363446a0","article-title":"Naturally occurring antibodies devoid of light chains","volume":"363","author":"Hamers-Casterman","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2020.04.030_bb0150","doi-asserted-by":"crossref","first-page":"21834","DOI":"10.1038\/srep21834","article-title":"In vivo detection of small tumour lesions by multi-pinhole SPECT applying a (99m)Tc-labelled nanobody targeting the epidermal growth factor receptor","volume":"6","author":"Kruwel","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0155","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s11307-015-0909-6","article-title":"Hypoxia-targeting fluorescent nanobodies for optical molecular imaging of pre-invasive breast cancer","volume":"18","author":"van Brussel","year":"2016","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0160","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2967\/jnumed.115.171306","article-title":"Preclinical evaluation of 18F-labeled anti-HER2 nanobody conjugates for imaging HER2 receptor expression by immuno-PET","volume":"57","author":"Vaidyanathan","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0165","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2967\/jnumed.115.162024","article-title":"Phase I study of 68Ga-HER2-nanobody for PET\/CT assessment of HER2 expression in breast carcinoma","volume":"57","author":"Keyaerts","year":"2016","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2020.04.030_bb0170","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2967\/jnumed.119.226712","article-title":"PET imaging of tumor PD-L1 expression with a highly specific non-blocking nanobody","volume":"61","author":"Lv","year":"2020","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0175","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1021\/acs.molpharmaceut.7b00789","article-title":"Molecular imaging of Mesothelin-expressing ovarian cancer with a human and mouse cross-reactive nanobody","volume":"15","author":"Prantner","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0180","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.2967\/jnumed.115.156729","article-title":"A novel (1)(1)(1)in-labeled anti-prostate-specific membrane antigen Nanobody for targeted SPECT\/CT imaging of prostate cancer","volume":"56","author":"Chatalic","year":"2015","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0185","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1002\/ijc.28601","article-title":"Intraoperative fluorescence delineation of head and neck cancer with a fluorescent anti-epidermal growth factor receptor nanobody","volume":"134","author":"van Driel","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2020.04.030_bb0190","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s11307-017-1134-2","article-title":"Improved Debulking of peritoneal tumor implants by near-infrared fluorescent nanobody image guidance in an experimental mouse model","volume":"20","author":"Debie","year":"2018","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0195","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1021\/acs.molpharmaceut.9b00354","article-title":"Labeling of anti-HER2 nanobodies with astatine-211: optimization and the effect of different coupling reagents on their in vivo behavior","volume":"16","author":"Dekempeneer","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0200","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.nucmedbio.2017.09.003","article-title":"Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation","volume":"56","author":"Choi","year":"2018","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0205","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.nucmedbio.2016.01.002","article-title":"(18)F-nanobody for PET imaging of HER2 overexpressing tumors","volume":"43","author":"Xavier","year":"2016","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0210","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2967\/jnumed.113.127100","article-title":"Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling","volume":"55","author":"Pruszynski","year":"2014","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0215","first-page":"4900","article-title":"Endocytosis of EGFR requires its kinase activity and N-terminal transmembrane dimerization motif","volume":"126","author":"Heukers","year":"2013","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0220","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2310\/7290.2011.00025","article-title":"Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody","volume":"11","author":"Oliveira","year":"2012","journal-title":"Mol. Imaging"},{"key":"10.1016\/j.jconrel.2020.04.030_bb0225","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1007\/s00259-013-2471-2","article-title":"Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery","volume":"40","author":"Kijanka","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2020.04.030_bb0230","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jconrel.2013.08.298","article-title":"Targeting tumors with nanobodies for cancer imaging and therapy","volume":"172","author":"Oliveira","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.04.030_bb0235","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1364\/BOE.4.000696","article-title":"In vivo quantification of the scattering properties of tissue using multi-diameter single fiber reflectance spectroscopy","volume":"4","author":"van Leeuwen-van Zaane","year":"2013","journal-title":"Biomed. Opt. Express."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0240","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/1471-2407-10-235","article-title":"Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivo in mice","volume":"10","author":"Hu","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jconrel.2020.04.030_bb0245","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/bjc.2011.88","article-title":"Effective treatment of chemoresistant breast cancer in vitro and in vivo by a factor VII-targeted photodynamic therapy","volume":"104","author":"Duanmu","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2020.04.030_bb0250","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1039\/c1pp05014a","article-title":"Targeted photodynamic therapy of breast cancer cells using antibody-phthalocyanine-gold nanoparticle conjugates","volume":"10","author":"Stuchinskaya","year":"2011","journal-title":"Photochem. Photobiol. Sci."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0255","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1039\/c4pp00312h","article-title":"Cancer targeting with biomolecules: a comparative study of photodynamic therapy efficacy using antibody or lectin conjugated phthalocyanine-PEG gold nanoparticles","volume":"14","author":"Obaid","year":"2015","journal-title":"Photochem. Photobiol. Sci."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0260","article-title":"Acute cellular and vascular responses to photodynamic therapy using EGFR-targeted nanobody-photosensitizer conjugates studied with intravital optical imaging and magnetic resonance imaging","author":"de Bruijn","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2020.04.030_bb0265","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1021\/acs.molpharmaceut.6b01053","article-title":"Effect of dye and conjugation chemistry on the biodistribution profile of near-infrared-labeled nanobodies as tracers for image-guided surgery","volume":"14","author":"Debie","year":"2017","journal-title":"Mol. Pharm."},{"issue":"6","key":"10.1016\/j.jconrel.2020.04.030_bb0270","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s11307-019-01320-x","article-title":"Imaging of tumor spheroids, dual-isotope SPECT, and autoradiographic analysis to assess the tumor uptake and distribution of different nanobodies","volume":"21","author":"Beltran Hernandez","year":"2019","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0275","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/j.1751-1097.2010.00760.x","article-title":"Fractionated illumination at low fluence rate photodynamic therapy in mice","volume":"86","author":"Middelburg","year":"2010","journal-title":"Photochem. Photobiol."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0280","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/lsm.22930","article-title":"Epidermal growth factor receptor (EGFR) density may not be the only determinant for the efficacy of EGFR-targeted photoimmunotherapy in human head and neck cancer cell lines","volume":"50","author":"Peng","year":"2018","journal-title":"Lasers Surg. Med."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0285","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/ijc.30844","article-title":"Porphyrin modified trastuzumab improves efficacy of HER2 targeted photodynamic therapy of gastric cancer","volume":"141","author":"Korsak","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2020.04.030_bb0290","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1021\/acs.bioconjchem.7b00144","article-title":"Near-infrared photochemoimmunotherapy by photoactivatable bifunctional antibody-drug conjugates targeting human epidermal growth factor receptor 2 positive cancer","volume":"28","author":"Ito","year":"2017","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0295","doi-asserted-by":"crossref","first-page":"22945","DOI":"10.18632\/oncotarget.25159","article-title":"Using antibody directed phototherapy to target oesophageal adenocarcinoma with heterogeneous HER2 expression","volume":"9","author":"Pye","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2020.04.030_bb0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113276","article-title":"Photoimmunotherapy of gastric cancer peritoneal carcinomatosis in a mouse model","volume":"9","author":"Sato","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2020.04.030_bb0305","doi-asserted-by":"crossref","first-page":"14143","DOI":"10.18632\/oncotarget.7490","article-title":"Combination photoimmunotherapy with monoclonal antibodies recognizing different epitopes of human epidermal growth factor receptor 2: an assessment of phototherapeutic effect based on fluorescence molecular imaging","volume":"7","author":"Ito","year":"2016","journal-title":"Oncotarget."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0310","doi-asserted-by":"crossref","first-page":"6471","DOI":"10.1158\/0008-5472.CAN-13-0657","article-title":"Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization","volume":"73","author":"Li","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0315","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1572-1000(04)00007-9","article-title":"Photosensitizers in clinical PDT","volume":"1","author":"Allison","year":"2004","journal-title":"Photodiagn. Photodyn. Ther."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0320","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00262-014-1633-9","article-title":"Development of photodynamic therapy regimens that control primary tumor growth and inhibit secondary disease","volume":"64","author":"Shams","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0325","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.pdpdt.2015.06.009","article-title":"Inhibitory and immunological effects induced by the combination of photodynamic therapy and dendritic cells on mouse transplanted hepatoma","volume":"13","author":"Zhang","year":"2016","journal-title":"Photodiagn. Photodyn. Ther."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0330","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1158\/1078-0432.CCR-15-0515","article-title":"Combination of photodynamic therapy and specific immunotherapy efficiently eradicates established tumors","volume":"22","author":"Kleinovink","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0335","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9020333","article-title":"Preclinical and clinical evidence of immune responses triggered in oncologic photodynamic therapy: clinical recommendations","volume":"9","author":"Beltran Hernandez","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0340","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1073\/pnas.89.12.5321","article-title":"ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization","volume":"89","author":"Kallioniemi","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0345","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5858\/2010-0454-RAR.1","article-title":"HER2: biology, detection, and clinical implications","volume":"135","author":"Gutierrez","year":"2011","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0350","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1021\/nn304872n","article-title":"In vivo targeted deep-tissue photodynamic therapy based on near-infrared light triggered upconversion nanoconstruct","volume":"7","author":"Cui","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2020.04.030_bb0355","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1002\/cam4.752","article-title":"Photoimmunotherapy of residual disease after incomplete surgical resection in head and neck cancer models","volume":"5","author":"Moore","year":"2016","journal-title":"Cancer Med."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0360","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.7150\/thno.35274","article-title":"Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors","volume":"9","author":"Lutje","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2020.04.030_bb0365","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/annonc\/mdv161","article-title":"Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration","volume":"26","author":"Bossuyt","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0370","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.clon.2017.06.003","article-title":"Neoadjuvant therapy in early breast cancer: treatment considerations and common debates in practice","volume":"29","author":"Cain","year":"2017","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"10.1016\/j.jconrel.2020.04.030_bb0375","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1200\/JCO.2009.24.9284","article-title":"Breast cancer subtypes and the risk of local and regional relapse","volume":"28","author":"Voduc","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0380","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/1477-7819-12-289","article-title":"HER-2 positive breast cancer is associated with an increased risk of positive cavity margins after initial lumpectomy","volume":"12","author":"Jia","year":"2014","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0385","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2217\/nnm.14.178","article-title":"Nanobody-based cancer therapy of solid tumors","volume":"10","author":"Kijanka","year":"2015","journal-title":"Nanomedicine (London)"},{"key":"10.1016\/j.jconrel.2020.04.030_bb0390","doi-asserted-by":"crossref","first-page":"708","DOI":"10.7150\/thno.8156","article-title":"Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody","volume":"4","author":"D\u2019Huyvetter","year":"2014","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2020.04.030_bb0395","first-page":"8","article-title":"Nanobody engineering: toward next generation immunotherapies and immunoimaging of cancer","author":"Chanier","year":"2019","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.jconrel.2020.04.030_bb0400","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/cbic.201500591","article-title":"A nanobody activation immunotherapeutic that selectively destroys HER2-positive breast cancer cells","volume":"17","author":"Gray","year":"2016","journal-title":"Chembiochem"},{"key":"10.1016\/j.jconrel.2020.04.030_bb0405","first-page":"1259","article-title":"A HER2 bispecific antibody can be efficiently expressed in Escherichia coli with potent cytotoxicity","volume":"16","author":"Lin","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0410","doi-asserted-by":"crossref","first-page":"852748","DOI":"10.1155\/2014\/852748","article-title":"Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Mol. Biol. Int."},{"key":"10.1016\/j.jconrel.2020.04.030_bb0415","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10555-015-9552-6","article-title":"HER2 expression status in diverse cancers: review of results from 37,992 patients","volume":"34","author":"Yan","year":"2015","journal-title":"Cancer Metastasis Rev."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920302443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920302443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:50:30Z","timestamp":1759161030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365920302443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":83,"alternative-id":["S0168365920302443"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.04.030","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.04.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}